Uniqure Nv Stock Performance
| QURE Stock | USD 5.97 0.05 0.83% |
On a scale of 0 to 100, Uniqure NV holds a performance score of 3. The entity has a beta of 4.28, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Uniqure NV will likely underperform. Please check Uniqure NV's semi variance, and the relationship between the treynor ratio and daily balance of power , to make a quick decision on whether Uniqure NV's existing price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Uniqure NV are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of rather uncertain basic indicators, Uniqure NV exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return (0.50) | Five Day Return 2.73 | Year To Date Return (13.13) | Ten Year Return (55.17) | All Time Return (58.80) |
Last Split Factor 1:5 | Last Split Date 2014-01-31 |
1 | Acquisition by Jacques Rachelle Suzanne of 8080 shares of Uniqure NV subject to Rule 16b-3 | 09/16/2024 |
2 | Acquisition by Gut Robert of 17060 shares of Uniqure NV at 20.18 subject to Rule 16b-3 | 09/26/2024 |
3 | Pfizer Secures FDA Approval for Hemophilia Drug Hympavzi | 10/14/2024 |
4 | uniQure Announces Dosing of First Patient in Phase III Clinical Trial of AMT-162 for the Treatment SOD1-ALS | 10/15/2024 |
5 | Disposition of 3228 shares by Gut Robert of Uniqure NV at 18.88 subject to Rule 16b-3 | 10/22/2024 |
6 | Multiple Insiders Sold uniQure Shares Presenting Weak Signs For Investors | 11/01/2024 |
7 | uniQure Announces Third Quarter 2024 Financial Resultsand Highlights Recent Company Progress | 11/05/2024 |
8 | Wall Street Analysts Believe uniQure Could Rally 169.18 percent Heres is How to Trade | 11/08/2024 |
9 | uniQure Announces Third Quarter Financial Results and Recent Progress | 11/14/2024 |
10 | Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU | 11/21/2024 |
| Begin Period Cash Flow | 231.2 M |
Uniqure |
Uniqure NV Relative Risk vs. Return Landscape
If you would invest 557.00 in Uniqure NV on August 31, 2024 and sell it today you would earn a total of 40.00 from holding Uniqure NV or generate 7.18% return on investment over 90 days. Uniqure NV is currently generating 0.2675% in daily expected returns and assumes 5.8356% risk (volatility on return distribution) over the 90 days horizon. In different words, 51% of stocks are less volatile than Uniqure, and 95% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Uniqure NV Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Uniqure NV's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Uniqure NV, and traders can use it to determine the average amount a Uniqure NV's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0458
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | QURE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.84 actual daily | 52 52% of assets are less volatile |
Expected Return
| 0.27 actual daily | 5 95% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Uniqure NV is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Uniqure NV by adding it to a well-diversified portfolio.
Uniqure NV Fundamentals Growth
Uniqure Stock prices reflect investors' perceptions of the future prospects and financial health of Uniqure NV, and Uniqure NV fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Uniqure Stock performance.
| Return On Equity | -1.48 | ||||
| Return On Asset | -0.17 | ||||
| Operating Margin | (17.77) % | ||||
| Current Valuation | (74.21 M) | ||||
| Shares Outstanding | 48.74 M | ||||
| Price To Earning | 2.51 X | ||||
| Price To Book | 5.26 X | ||||
| Price To Sales | 10.26 X | ||||
| Revenue | 15.84 M | ||||
| Gross Profit | (87.37 M) | ||||
| EBITDA | (253.1 M) | ||||
| Net Income | (308.48 M) | ||||
| Cash And Equivalents | 500.52 M | ||||
| Cash Per Share | 10.71 X | ||||
| Total Debt | 138.41 M | ||||
| Debt To Equity | 0.29 % | ||||
| Current Ratio | 10.84 X | ||||
| Book Value Per Share | 1.15 X | ||||
| Cash Flow From Operations | (145.93 M) | ||||
| Earnings Per Share | (4.95) X | ||||
| Market Capitalization | 293.43 M | ||||
| Total Asset | 831.69 M | ||||
| Retained Earnings | (890.41 M) | ||||
| Working Capital | 578.18 M | ||||
| Current Asset | 209.49 M | ||||
| Current Liabilities | 24.38 M | ||||
About Uniqure NV Performance
By analyzing Uniqure NV's fundamental ratios, stakeholders can gain valuable insights into Uniqure NV's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Uniqure NV has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Uniqure NV has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 322.04 | 338.14 | |
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.37) | (0.39) | |
| Return On Assets | (0.37) | (0.39) | |
| Return On Equity | (1.49) | (1.41) |
Things to note about Uniqure NV performance evaluation
Checking the ongoing alerts about Uniqure NV for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Uniqure NV help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Uniqure NV had very high historical volatility over the last 90 days | |
| Uniqure NV has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 15.84 M. Net Loss for the year was (308.48 M) with loss before overhead, payroll, taxes, and interest of (87.37 M). | |
| Uniqure NV currently holds about 500.52 M in cash with (145.93 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 10.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Uniqure NV has a frail financial position based on the latest SEC disclosures | |
| Over 82.0% of the company shares are owned by institutional investors | |
| Latest headline from zacks.com: Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU |
- Analyzing Uniqure NV's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Uniqure NV's stock is overvalued or undervalued compared to its peers.
- Examining Uniqure NV's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Uniqure NV's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Uniqure NV's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Uniqure NV's stock. These opinions can provide insight into Uniqure NV's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Uniqure Stock analysis
When running Uniqure NV's price analysis, check to measure Uniqure NV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Uniqure NV is operating at the current time. Most of Uniqure NV's value examination focuses on studying past and present price action to predict the probability of Uniqure NV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Uniqure NV's price. Additionally, you may evaluate how the addition of Uniqure NV to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |